The largest analysis of its kind has found that Caucasians are much more likely than people in other racial/ethnic groups to develop a rare bone and soft tissue cancer called Ewing’s sarcoma. In addition, among Caucasians with this cancer, men are more likely to die than women. Published in the...
Latest News
Houston, Texas – Researchers from The University of Texas MD Anderson Cancer Center reported promising results in a Phase I/II trial of 37 patients with relapsed or refractory B-cell malignancies who were treated with cord blood-derived chimeric antigen receptor (CAR) natural killer (NK) cell therapy targeting CD19. Published today in Nature...
Osaka, Japan – Much like ripples on the water can betray powerful currents below the surface, small changes in our bodies can sometimes be an indicator of a serious condition. Now, researchers from Japan say that cells in the blood may provide telltale signs of important immune dysfunction. In a...
Among patients with CD70-positive acute myeloid leukemia (AML), CD-70 targeting chimeric antigen receptor (CAR) T-cell therapy may be a promising therapeutic strategy, according to a cell line-based study published in Blood. AML is the most commonly diagnosed leukemia subtype among adults. Although treatment options have improved over the past several decades,...
DANBURY, Conn. & AUSTIN, Texas – CDISC and the National Organization for Rare Disorders (NORD®) have announced a partnership to develop global data standards for rare diseases. The data standards will be released in a Therapeutic Area User Guide that will be available at no cost on the CDISC website for researchers to...
CEBPA basic leucine zipper (CEBPA-bZip) mutations, whether monoallelic or biallelic, are associated with favorable outcomes from acute myeloid leukemia (AML), similar to those with CEBPA-double-mutated (CEBPA-dm), according to research published in Blood. CEBPA mutations are a common driver for AML and occur in 4% to 11% of patients. This analysis evaluated outcomes data across CEBPA mutation...
VIENNA, Va. — CEL-SCI Corporation (NYSE AMEX: CVM) announced today that its collaborators at the University of Hawaii reported on data at the annual American Society for Microbiology in Philadelphia, PA. This data demonstrates that vaccines utilizing its L.E.A.P.S.(TM) (Ligand Epitope Antigen Presentation System) vaccine technology with specificity for particular...
MINNEAPOLIS, Minn. — Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company developing targeted therapies for oncology, today announced that the first patient has been dosed in its Phase 1b/2 study (CELC-G-201) evaluating gedatolisib in combination with Nubeqa® (darolutamide), an approved androgen receptor inhibitor, for the treatment of patients with metastatic...
CAMBRIDGE, Mass. – QurAlis Corporation, a biotech company developing breakthrough precision medicines for ALS and other genetically validated neurodegenerative diseases, today announced the publication of an article in Cell Reports titled Human Amyotrophic Lateral Sclerosis Excitability Phenotype Screen: Target Discovery and Validation by QurAlis founders Kasper Roet, Ph.D., Clifford Woolf, M.D., Ph.D., and Kevin Eggan, Ph.D., who...
MIAMI, FLORIDA – A study led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine suggests that CAR-T immunotherapy remains a viable option for patients who have lymphoma that goes into remission before the cell therapy begins. While the study doesn’t answer the...